Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Payables (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Payables for 11 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • Quarterly Payables fell 58.76% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, down 58.76% year-over-year, with the annual reading at $1.7 million for FY2025, 58.76% down from the prior year.
  • Payables hit $1.7 million in Q4 2025 for Seres Therapeutics, roughly flat from $1.7 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $18.0 million in Q3 2021 to a low of $1.7 million in Q3 2025.
  • Historically, Payables has averaged $8.4 million across 5 years, with a median of $8.2 million in 2021.
  • Biggest five-year swings in Payables: skyrocketed 207.13% in 2021 and later plummeted 79.68% in 2025.
  • Year by year, Payables stood at $13.7 million in 2021, then soared by 30.29% to $17.9 million in 2022, then tumbled by 79.65% to $3.6 million in 2023, then increased by 12.03% to $4.1 million in 2024, then tumbled by 58.76% to $1.7 million in 2025.
  • Business Quant data shows Payables for MCRB at $1.7 million in Q4 2025, $1.7 million in Q3 2025, and $2.2 million in Q2 2025.